Global SRS and Stereotactic Radiotherapy (SRT) Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

SRS & Stereotactic Radiotherapy (SRT) Market Size

• The global SRS & stereotactic radiotherapy (SRT) market size was valued at USD 9.8 billion in 2025and is expected to reach USD 18.6 billion by 2033, at a CAGR of 8.3% during the forecast period
• Growth is driven by increasing prevalence of cancer, particularly brain tumors, lung cancer, and metastatic lesions requiring precision radiation therapy
• Rising adoption of non-invasive and minimally invasive treatment modalities is accelerating demand for SRS/SRT systems across hospitals and specialty clinics
• Technological advancements in image-guided radiotherapy (IGRT), AI-based treatment planning, and robotic radiosurgery systems are further supporting market expansion

SRS & Stereotactic Radiotherapy (SRT) Market Analysis

• SRS and SRT systems deliver high-dose radiation with sub-millimeter precision, minimizing damage to surrounding tissues, making them essential in oncology and neurological treatments
• The escalating demand is primarily driven by increasing cancer incidence, growing geriatric population, and rising preference for outpatient and non-surgical treatments
• North America dominated the market with the largest revenue share of 38.7% in 2025, supported by advanced healthcare infrastructure, high adoption of robotic radiosurgery systems, and strong reimbursement frameworks
• Asia-Pacific is expected to be the fastest-growing region due to rising cancer burden, improving healthcare access, and increasing installation of radiotherapy systems in countries such as China and India
• The linear accelerator (LINAC)-based SRT segment dominated the market with a share of 42.5% in 2025, driven by widespread availability, cost-effectiveness, and versatility across multiple cancer indications

Report Scope and SRS & Stereotactic Radiotherapy (SRT) Market Segmentation

SRS & Stereotactic Radiotherapy (SRT) Market Trends

“Rising Adoption of Precision, Image-Guided, and AI-Enabled Radiotherapy Solutions”

• A significant and accelerating trend in the global SRS & stereotactic radiotherapy (SRT) market is the growing shift toward precision-driven, image-guided, and minimally invasive radiotherapy solutions that enhance treatment accuracy while reducing damage to surrounding healthy tissues across multiple oncology applications
• For instance, companies such as Varian Medical Systems and Elekta AB are increasingly developing advanced SRS & SRT systems integrated with real-time imaging, adaptive radiotherapy, and AI-based treatment planning to improve targeting accuracy and clinical outcomes
• Technological advancements in treatment planning software, motion management, and radiation delivery systems are enabling the development of SRS & SRT solutions with improved targeting precision, reduced treatment time, and enhanced patient safety, helping healthcare providers maintain high treatment efficacy
• The increasing adoption of non-invasive cancer treatments and outpatient radiotherapy procedures is supporting the demand for SRS & SRT systems that enhance patient comfort, reduce hospitalization time, and improve recovery outcomes
• This trend toward high-precision and technology-integrated radiotherapy solutions is reshaping industry expectations for clinical efficiency, treatment outcomes, and healthcare infrastructure modernization across hospitals and cancer treatment centers
• The demand for advanced SRS & SRT systems with improved automation, workflow integration, and AI-enabled capabilities is growing rapidly across both developed and emerging healthcare markets, driven by rising cancer incidence and increasing healthcare investments
• Increasing adoption of personalized oncology and adaptive radiotherapy approaches is gaining traction due to rising emphasis on patient-specific treatment planning and improved therapeutic outcomes across global healthcare systems.

SRS & Stereotactic Radiotherapy (SRT) Market Dynamics

Driver

“Rising Demand for Non-Invasive and High-Precision Cancer Treatment Solutions”

• The increasing demand for non-invasive, high-precision, and targeted cancer treatment solutions, coupled with the rising global burden of cancer, is a major driver fueling the growth of the SRS & stereotactic radiotherapy (SRT) market globally
• For instance, healthcare systems in regions such as North America and Europe are increasingly adopting advanced radiotherapy technologies to improve treatment outcomes and reduce surgical interventions
• As healthcare providers focus more on improving clinical efficiency and patient outcomes, SRS & SRT systems offer precise tumor targeting, reduced side effects, and shorter treatment durations compared to conventional radiotherapy methods
• Furthermore, the growing shift toward outpatient care and minimally invasive procedures, supported by advancements in radiotherapy technologies, is increasing the adoption of SRS & SRT systems across hospitals and cancer treatment centers
• The versatility of these systems across applications such as brain tumors, lung cancer, spine lesions, and prostate cancer, along with their ability to deliver high-dose radiation with minimal invasiveness, is driving widespread adoption
• Expanding healthcare infrastructure and rising healthcare expenditure in emerging economies are further supporting market expansion through increased installation of advanced radiotherapy systems
• Government initiatives and investments aimed at improving cancer care infrastructure and access to advanced treatment technologies are accelerating the adoption and commercialization of SRS & SRT solutions

Restraint/Challenge

“High Capital Investment and Infrastructure Requirements”

• Challenges related to the high cost of SRS & stereotactic radiotherapy (SRT) systems, along with significant infrastructure and maintenance requirements, pose major barriers to large-scale adoption, particularly in developing and price-sensitive markets
• For instance, installation of advanced systems such as proton therapy and robotic radiosurgery requires substantial capital investment, specialized facilities, and skilled professionals
• Addressing these challenges through technological innovation, cost optimization, and public-private partnerships is critical for enhancing accessibility and market penetration
• While demand for advanced radiotherapy solutions is increasing, limited availability of trained professionals and technical expertise can restrict adoption in certain regions
• Overcoming these challenges through training programs, workflow automation, and integration of AI-based systems will be essential for long-term market growth, while infrastructure limitations can impact deployment in low-resource settings
• Stringent regulatory approvals and compliance requirements can also increase time-to-market and operational complexity for manufacturers, potentially affecting product adoption and expansion timelines

SRS & Stereotactic Radiotherapy (SRT) Market Scope

The market is segmented on the basis of technology type, treatment type, application, end user, component, and radiation type.

• By Technology Type

On the basis of technology type, the global SRS & stereotactic radiotherapy (SRT) market is segmented into Gamma Knife, Linear Accelerator (LINAC), Proton Beam Therapy, CyberKnife, and others. The linear accelerator (LINAC) segment dominated the market with the largest revenue share of approximately 42.5% in 2025, driven by its widespread availability, cost-effectiveness, and versatility in treating a wide range of cancers including brain, lung, and prostate tumors. LINAC systems are widely preferred due to their adaptability in delivering both SRS and SRT treatments along with integration capabilities with advanced imaging and treatment planning systems. Their increasing installation across hospitals and cancer treatment centers, along with continuous technological advancements, is further strengthening segment dominance globally.

The proton beam therapy segment is expected to witness the fastest growth during the forecast period, fueled by its superior dose distribution capabilities and ability to minimize radiation exposure to surrounding healthy tissues. Increasing investments in proton therapy centers, along with growing awareness regarding its clinical benefits in pediatric and complex cancer cases, are driving adoption. Technological advancements and expanding infrastructure are further accelerating segment growth globally.

• By Treatment Type

On the basis of treatment type, the market is segmented into stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT/SRT). The SBRT/SRT segment dominated the market with the largest revenue share in 2025, driven by its increasing use in treating extracranial tumors such as lung, liver, and prostate cancers. SBRT offers high precision, reduced treatment sessions, and improved patient outcomes, making it highly preferred in modern oncology practices. Its growing adoption in outpatient settings and cancer treatment centers is further supporting segment growth globally.

The SRS segment is expected to witness significant growth during the forecast period, fueled by rising prevalence of neurological disorders and brain tumors. Increasing use of SRS in treating intracranial conditions such as metastases, arteriovenous malformations, and trigeminal neuralgia is driving demand. Advancements in imaging and targeting technologies are further enhancing its clinical applications and accelerating segment growth.

• By Application

On the basis of application, the SRS & stereotactic radiotherapy (SRT) market is segmented into brain tumors, lung cancer, spine tumors, prostate cancer, liver cancer, breast cancer, and others. The brain tumors segment dominated the market with the largest revenue share in 2025, supported by the high adoption of Gamma Knife and CyberKnife systems for precise intracranial treatments. Increasing incidence of brain metastases and neurological conditions is driving demand for SRS-based treatments. The ability to deliver high-dose radiation with minimal damage to surrounding tissues further strengthens segment dominance.

The lung cancer segment is expected to witness the fastest growth during the forecast period, driven by rising global prevalence of lung cancer and increasing adoption of SBRT as a preferred treatment option for early-stage tumors. Technological advancements in motion management and real-time imaging are enhancing treatment accuracy, further accelerating segment growth globally.

• By End User

On the basis of end user, the market is segmented into hospitals, cancer treatment centers, ambulatory surgical centers, and research institutes. The hospitals segment dominated the market with the largest revenue share in 2025, driven by the availability of advanced infrastructure, skilled professionals, and integrated oncology care facilities. Hospitals are primary adopters of high-cost radiotherapy systems due to their financial capabilities and patient volume, supporting widespread utilization.

The cancer treatment centers segment is expected to witness the fastest growth during the forecast period, fueled by increasing specialization in oncology care and rising demand for dedicated radiotherapy services. These centers focus on high patient throughput and advanced treatment technologies, further driving adoption of SRS and SRT systems globally.

• By Component

On the basis of component, the SRS & stereotactic radiotherapy (SRT) market is segmented into equipment, software (treatment planning systems), and services (maintenance and upgrades). The equipment segment dominated the market with the largest revenue share in 2025, driven by the high capital cost associated with radiotherapy systems such as LINAC, Gamma Knife, and proton therapy units. Increasing installations of these systems across healthcare facilities are contributing to segment growth.

The software segment is expected to witness the fastest growth during the forecast period, fueled by increasing adoption of AI-based treatment planning, image-guided radiotherapy, and workflow optimization solutions. Continuous advancements in software technologies are enhancing treatment precision and operational efficiency, further accelerating segment growth globally.

• By Radiation Type

On the basis of radiation type, the market is segmented into photon-based therapy and proton-based therapy. The photon-based therapy segment dominated the market with the largest revenue share in 2025, supported by its widespread use, cost-effectiveness, and established clinical efficacy across multiple cancer types. Most existing radiotherapy systems operate on photon-based technologies, contributing to its strong market presence.

The proton-based therapy segment is expected to witness the fastest growth during the forecast period, driven by its ability to deliver targeted radiation with minimal side effects. Increasing investments in proton therapy infrastructure and rising awareness of its clinical advantages are supporting rapid adoption across advanced healthcare markets.

SRS & Stereotactic Radiotherapy (SRT) Market Regional Analysis

• North America dominated the market with the largest revenue share of 38.7% in 2025, supported by advanced healthcare infrastructure, high adoption of robotic radiosurgery systems, and strong reimbursement frameworks
• Healthcare providers and institutions in the region place significant emphasis on improving access to advanced cancer treatment, cost-effective healthcare delivery, and expanding radiotherapy capacity, leading to widespread utilization of SRS & SRT systems across both public and private healthcare facilities
• This strong market position is further supported by rising government initiatives to strengthen oncology care infrastructure, increasing investments in healthcare technologies, and growing awareness regarding early cancer diagnosis and advanced treatment options, establishing SRS & SRT systems as essential components in modern cancer treatment across the region

U.S. SRS & Stereotactic Radiotherapy (SRT) Market Insight

The U.S. SRS & stereotactic radiotherapy (SRT) market captured the largest revenue share within North America in 2025, driven by advanced healthcare infrastructure, high adoption of cutting-edge radiotherapy technologies, and strong presence of leading market players such as Varian Medical Systems and Accuray Incorporated. Healthcare providers increasingly prioritize precision oncology and minimally invasive treatment approaches to improve patient outcomes and reduce treatment time. The growing adoption of AI-integrated treatment planning systems and robotic radiosurgery platforms continues to propel market growth, supported by favorable reimbursement policies and strong clinical research ecosystem.

Europe SRS & Stereotactic Radiotherapy (SRT) Market Insight

The Europe SRS & stereotactic radiotherapy (SRT) market is projected to expand at a steady CAGR throughout the forecast period, primarily driven by increasing cancer incidence, strong regulatory frameworks, and growing adoption of advanced radiotherapy technologies. European healthcare systems emphasize high-quality treatment standards, early diagnosis, and precision medicine approaches, fostering consistent adoption of SRS & SRT systems across hospitals and cancer treatment centers. Growth is supported by government funding, technological advancements, and increasing integration of digital health solutions in oncology care

U.K. SRS & Stereotactic Radiotherapy (SRT) Market Insight

The U.K. SRS & stereotactic radiotherapy (SRT) market is anticipated to grow at a notable CAGR during the forecast period, supported by increasing demand for advanced cancer treatment solutions and strong healthcare infrastructure. Rising prevalence of cancer and growing focus on improving radiotherapy capacity are driving demand across the country. The presence of well-established healthcare systems and ongoing investments in oncology technologies are accelerating adoption of SRS & SRT systems. In addition, increasing emphasis on precision medicine and patient-centered care enhances market growth across the healthcare value chain

Germany SRS & Stereotactic Radiotherapy (SRT) Market Insight

The Germany SRS & stereotactic radiotherapy (SRT) market is expected to expand at a considerable CAGR during the forecast period, driven by strong demand for advanced medical technologies and leadership in healthcare innovation. High emphasis on precision treatment, regulatory compliance, and technological advancement supports the adoption of SRS & SRT systems across hospitals and specialized cancer centers. Germany’s focus on research and development, along with integration of advanced imaging and radiotherapy technologies, promotes the use of high-performance radiotherapy solutions

Asia-Pacific SRS & Stereotactic Radiotherapy (SRT) Market Insight

The Asia-Pacific SRS & stereotactic radiotherapy (SRT) market is poised to grow at the fastest CAGR during the forecast period of 2026 to 2033, driven by rising cancer prevalence, improving healthcare infrastructure, and increasing investments in advanced treatment technologies. Countries such as China, India, Japan, and South Korea play a key role in both adoption and expansion of radiotherapy systems. Rising healthcare expenditure and growing awareness regarding early cancer treatment are accelerating adoption. In addition, government initiatives to enhance oncology care and expand radiotherapy accessibility further support market growth across the region

Japan SRS & Stereotactic Radiotherapy (SRT) Market Insight

The Japan SRS & stereotactic radiotherapy (SRT) market is gaining momentum due to increasing focus on advanced healthcare technologies and precision oncology. Strong emphasis on high-quality treatment standards and early cancer detection is driving adoption of SRS & SRT systems. The growing demand for minimally invasive and high-precision treatment options supports long-term market growth. Integration of advanced imaging systems and robotic radiotherapy platforms continues to enhance treatment outcomes and expand application scope across healthcare facilities

India SRS & Stereotactic Radiotherapy (SRT) Market Insight

The India SRS & stereotactic radiotherapy (SRT) market accounted for a significant revenue share in Asia-Pacific in 2025, attributed to rising cancer incidence, improving healthcare access, and increasing investments in oncology infrastructure. Expanding healthcare facilities and growing demand for advanced treatment options are driving adoption. SRS & SRT systems are increasingly being installed across hospitals and specialized cancer centers due to their effectiveness in non-invasive cancer treatment. Government initiatives aimed at strengthening cancer care infrastructure and increasing accessibility to advanced radiotherapy technologies are key factors supporting sustained market expansion in India.

SRS & Stereotactic Radiotherapy (SRT) Market Share

The SRS & stereotactic radiotherapy (SRT) industry is primarily led by well-established companies, including:

• Varian Medical Systems (Siemens Healthineers) (U.S.)
• Elekta AB (Sweden)
• Accuray Incorporated (U.S.)
• Brainlab AG (Germany)
• ViewRay Technologies, Inc. (U.S.)
• Mevion Medical Systems (U.S.)
• Hitachi Ltd. (Japan)
• Ion Beam Applications SA (IBA) (Belgium)
• Panacea Medical Technologies (India)
• Canon Medical Systems Corporation (Japan)
• Shinva Medical Instrument Co., Ltd. (China)
• Mitsubishi Electric Corporation (Japan)
• RaySearch Laboratories AB (Sweden)
• ProTom International (U.S.)
• Nordion Inc. (Canada)
• Sumitomo Heavy Industries Ltd. (Japan)
• ZEISS Group (Germany)
• Standard Imaging Inc. (U.S.)
• CIVCO Medical Solutions (U.S.)
• PTW Freiburg GmbH (Germany)

What are the Recent Developments in Global SRS & Stereotactic Radiotherapy (SRT) Market?

• In January 2026, Elekta AB received U.S. FDA 510(k) clearance for its Elekta Evo CT-Linac system, enabling advanced adaptive radiotherapy with improved imaging precision and real-time treatment adjustments for enhanced clinical outcomes
• In December 2025, Elekta AB showcased its AI-powered online adaptive radiotherapy platform “Evo” featuring high-definition imaging and real-time treatment adaptation capabilities aimed at improving precision oncology workflows and patient-specific treatment delivery
• In September 2025, Accuray Incorporated launched an all-in-one radiotherapy solution platform designed to provide advanced treatment flexibility, adaptive care capabilities, and improved workflow efficiency for cancer treatment centers
• In June 2025, RaySearch Laboratories AB introduced RayCare v2025, an advanced oncology information system aimed at improving clinical workflow efficiency, interoperability, and data integration across radiotherapy treatment planning and delivery systems
• In December 2025, Varian Medical Systems collaborated with Telix Pharmaceuticals to explore integration of theranostics with external beam radiotherapy, focusing on enhancing targeted cancer treatment and improving patient selection strategies
• In September 2025, ZAP Surgical Systems introduced the next-generation ZAP-X radiosurgery platform with gyroscopic mobility, enabling highly precise radiation delivery from multiple angles to improve tumor targeting while preserving healthy brain tissue

SKU-76209